Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entia Biosciences, Inc.ERGO · Entity 178755 | Director · Chairman, CSTO | February 14, 2017 | February 17, 2017 |
| LUDWIG ENTERPRISES, INC.LUDG · Entity 8545 | 10% owner | April 20, 2026 | May 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entia Biosciences, Inc.
Report date February 14, 2017 · Filed February 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,188,900 |
Ending reported balance
After 2017-02-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2017-02-14 · Grant · Acquired 1,861,170 · Balance 8,838,900 Row 2 · 2017-02-14 · Grant · Acquired 600,000 · Balance 9,438,900 Row 3 · 2017-02-14 · Grant · Acquired 200,000 · Balance 9,638,900 Row 4 · 2017-02-14 · Grant · Acquired 300,000 · Balance 9,938,900 Row 5 · 2017-02-16 · Grant · Acquired 250,000 · Balance 10,188,900 |
LUDWIG ENTERPRISES, INC.
Report date April 20, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| common stockSEC Table I · non-derivative | Direct | 37,758,000 |
Ending reported balance
After 2026-04-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-20 · Sale · Disposed 1,500,000 · Balance 38,258,000 Row 2 · 2026-04-29 · Sale · Disposed 500,000 · Balance 37,758,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2026 Filed May 1, 2026 15:21 UTC | LUDWIG ENTERPRISES, INC. LUDG · Entity 8545 | Salecommon stock | 500,000 | $0.02 | $10,000.00 |
DisclosureSEC source: 0001067956-26-000004 · primary_doc.xml · nonDerivative · entry 2 HAUSMAN MARVIN S MD · CIK 0001067956 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,758,000 Read SEC document |
| April 20, 2026 Filed May 1, 2026 15:21 UTC | LUDWIG ENTERPRISES, INC. LUDG · Entity 8545 | Salecommon stock | 1,500,000 | $0.02 | $30,000.00 |
DisclosureSEC source: 0001067956-26-000004 · primary_doc.xml · nonDerivative · entry 1 HAUSMAN MARVIN S MD · CIK 0001067956 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,258,000 Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 00:19 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-17-000392 · form4-hausman021617.xml · nonDerivative · entry 5 HAUSMAN MARVIN S MD · CIK 0001067956 · Director · Chairman, CSTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,188,900 Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:19 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-17-000392 · form4-hausman021617.xml · nonDerivative · entry 4 HAUSMAN MARVIN S MD · CIK 0001067956 · Director · Chairman, CSTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,938,900 Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:19 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-17-000392 · form4-hausman021617.xml · nonDerivative · entry 3 HAUSMAN MARVIN S MD · CIK 0001067956 · Director · Chairman, CSTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,638,900 Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:19 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | GrantCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001185185-17-000392 · form4-hausman021617.xml · nonDerivative · entry 2 HAUSMAN MARVIN S MD · CIK 0001067956 · Director · Chairman, CSTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,438,900 Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 00:19 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | GrantCommon Stock | 1,861,170 | $0.18 | $325,704.75 |
DisclosureSEC source: 0001185185-17-000392 · form4-hausman021617.xml · nonDerivative · entry 1 HAUSMAN MARVIN S MD · CIK 0001067956 · Director · Chairman, CSTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,838,900 Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 02:57 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | PurchaseWarrant · Derivative | 40,000 | Not disclosed Strike: $0.10 | Not disclosed |
DisclosureSEC source: 0001185185-16-005908 · form4-hausman120616.xml · derivative · entry 2 HAUSMAN MARVIN S MD · CIK 0001067956 · Chairman,Chief Sci/Tech Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2021-12-05 F2 · price: As part of Unit. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 02:57 UTC | Entia Biosciences, Inc. ERGO · Entity 178755 | Purchase10% Convertible · Derivative | Not disclosed | $10,000.00 | $10,000.00 |
DisclosureSEC source: 0001185185-16-005908 · form4-hausman120616.xml · derivative · entry 1 HAUSMAN MARVIN S MD · CIK 0001067956 · Chairman,Chief Sci/Tech Offc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · Not disclosed shares Expires 2017-12-05 F1 · derivative.exercise_price: Holder has option of repayment or conversation into securities of the subject company's next financing. Terms and underlying securities of next financing, if and when such financing occurs, have yet to be determined. F1 · derivative.underlying_shares: Holder has option of repayment or conversation into securities of the subject company's next financing. Terms and underlying securities of next financing, if and when such financing occurs, have yet to be determined. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.